- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01919177
Effect of Inorganic Nitrates (Beetroot Juice) on Arterial Hemodynamics and Exercise Capacity
April 27, 2015 updated by: Julio A.Chirinos, Corporal Michael J. Crescenz VA Medical Center
Effect of Inorganic Nitrates on Arterial Hemodynamics and Exercise Capacity
The main objective is to test the hypothesis that inorganic nitrate supplementation will: (1) Improve exercise efficiency and performance; (2) Enhance the systemic vasodilator reserve during exercise and specifically, the vasodilator response in exercising muscle; (3) Reduce arterial wave reflections and arterial load; (4) Improve skeletal muscle mitochondrial function in subjects with heart failure with preserved ejection fraction.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This represents a series of double-blind, controlled pilot randomized studies in which the effects of nitrate-rich beetroot juice and nitrate-depleted beetroot juice will be assessed in patients with heart failure and preserved ejection fraction (n=20).
A total of 20 subjects will be enrolled over a 1.5 year period and randomized in a cross-over design to a single dose of nitrate-rich beetroot juice and nitrate-depleted beetroot juice.
The order of the interventions will be randomized; thus, all subjects will receive the nitrate-rich and nitrate-depleted juice, with a 4-7 day washout period in-between studies.
Study Type
Interventional
Enrollment (Actual)
17
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Philadelphia Veterans Affairs Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
The investigators will enroll 20 subjects >18 years of age who have a diagnosis of heart failure with preserved ejection fraction (>50%) by 2d echocardiography, with current New York Heart Association Class II-IV symptoms.
In addition, subjects with heart failure must meet the following inclusion criteria:
- Chronic treatment with a loop diuretic for control of HF symptoms.
- If EF is normal, subjects must demonstrate elevated filling pressures as evidenced by at least one of the following: a) left atrial enlargement (LAVI > 32 mL/m2); b) at least stage II diastolic dysfunction; c) Documentation of elevated NT-pro BNP levels or other natriuretic peptide marker (BNP, ANP) according to the laboratory and assay upper limit of normal in the previous year.
- Stable medical therapy as defined by: (I) No addition or removal of ACE, ARB, beta-blockers, or calcium channel blockers (CCBs) for 30 days. (II) No change in dosage of ACE, ARBs, beta-blockers or CCBs of more than 100% for 30 days. (III) No change in diuretic dose for 10 days.
Exclusion Criteria:
- Rhythm other than sinus rhythm (i.e., atrial fibrillation).
- Neuromuscular, orthopedic or other non-cardiac condition that prevents patient from exercising.
- Valve disease (> mild aortic or mitral stenosis; > moderate aortic or mitral regurgitation).
- Hypertrophic cardiomyopathy.
- Known infiltrative or inflammatory myocardial disease (amyloid, sarcoid).
- Pericardial disease.
- Primary pulmonary arteriopathy.
- Have experienced a myocardial infarction or unstable angina, or have undergone percutaneous transluminal coronary angiography (PTCA) or coronary artery bypass grafting (CABG) within 60 days prior to consent, or requires either PTCA or CABG at the time of consent.
- Other clinically important causes of dyspnea such as morbid obesity or significant lung disease defined by clinical judgment or use of steroids or oxygen for lung disease within the past 6 months.
- Systolic blood pressure < 110 mmHg or > 180 mm Hg.
- Diastolic blood pressure < 40 mmHg or > 100 mmHg.
- Resting heart rate (HR) > 100 bpm.
- Hemoglobin <10 g/dL.
- Patients with known severe liver disease (AST > 3x normal, alkaline phosphatase or bilirubin > 2x normal).
- Patients with a clinically indicated stress test demonstrating significant ischemia within a year of enrollment which was not followed by percutaneous or surgical revascularization.
- Current therapy with phosphodiesterase inhibitors, such as sildenafil, vardanafil or tadalafil.
- Known allergies to beetroot or lemon juice.
- Current use of organic nitrates or phosphodiesterase inhibitors.
- Pregnancy. Although beetroot juice has not knows teratogenic effects, we feel that not enough data exist in this regard. Therefore, all females patients of reproductive age will be required to undergo a pregnancy test prior to enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Nitrate rich beetroot juice
Subjects with heart failure with preserved ejection fraction will receive 140 mL of Nitrate-rich concentrated beetroot juice (containing 12 mmol of NO-3).
This will be a cross-over study.
Therefore all subjects will receive both interventions, but the order of the interventions will be randomized.
|
Subjects will receive 140 mL of Nitrate-rich concentrated beetroot juice.
Other Names:
|
Placebo Comparator: Nitrate depleted beetroot juice
Subjects with heart failure with preserved ejection fraction will receive 140 mL of nitrate-depleted beetroot juice (containing <0.01 mmol of NO-3).This will be a cross-over study.
Therefore all subjects will receive both interventions, but the order of the interventions will be randomized.
|
Subjects will receive 140 mL of nitrate-depleted beetroot juice.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Peak exercise efficiency during maximal effort supine-bicycle exercise and peak oxygen consumption (VO2) during a maximal effort supine-bicycle exercise test
Time Frame: Baseline study, repeat study 4-7 days later
|
We will assess the relationship between total power output and total O2 consumption (VO2, assessed via expired gas analysis) during a maximal-effort supine bicycle exercise test.
|
Baseline study, repeat study 4-7 days later
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Arterial wave reflection magnitude
Time Frame: Baseline study, repeat study 4-7 days later
|
Reflection wave magnitude will be assessed using arterial tonometry to arrive at the augmentation index.
The data will also be processed using custom designed software for wave separation analysis to quantify the magnitude and timing of the reflected waves.
|
Baseline study, repeat study 4-7 days later
|
Change in Peripheral vascular resistance, total arterial compliance and reflection magnitude during supine bicycle peak exercise
Time Frame: Baseline study, repeat study 4-7 days later
|
Baseline study, repeat study 4-7 days later
|
|
Change in lower extremity exercise vasodilator reserve (change in femoral vascular resistance between rest and maximal effort supine-bicycle exercise)
Time Frame: Baseline study, repeat study 4-7 days later
|
Baseline study, repeat study 4-7 days later
|
|
Change in lower extremity blood flow reserve (change in femoral artery blood flow between rest and maximal effort supine-bicycle exercise)
Time Frame: Baseline study, repeat study 4-7 days later
|
Baseline study, repeat study 4-7 days later
|
|
Change in submaximal exercise efficiency (O2 consumption per power output during submaximal exercise and standardized handgrip exercise)
Time Frame: Baseline study, repeat study 4-7 days later
|
Baseline study, repeat study 4-7 days later
|
|
Change in Skeletal Muscle Mitochondrial Oxidative Capacity
Time Frame: Baseline study, repeat study 4-7 days later
|
The investigators will assess the oxygen consumption recovery kinetics after moderate forearm exercise, using repeated cuff brachial artery occlusions and near-infrared spectroscopy.
|
Baseline study, repeat study 4-7 days later
|
Change in post-ischemic vasodilatory response
Time Frame: Baseline study, repeat study 4-7 days later
|
The investigators will assess the post-ischemic vasodilatory response in the forearm using brachial artery pulsed wave Doppler interrogations before and after inflation of a brachial cuff at 200 mmHg for 5 minutes.
The investigators will also assess forearm microvascular skeletal muscle flow with near-infrared spectroscopy and forearm skin microvascular flow using laser Doppler.
|
Baseline study, repeat study 4-7 days later
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- American Thoracic Society; American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003 Jan 15;167(2):211-77. doi: 10.1164/rccm.167.2.211. No abstract available. Erratum In: Am J Respir Crit Care Med. 2003 May 15;1451-2.
- Zamani P, Rawat D, Shiva-Kumar P, Geraci S, Bhuva R, Konda P, Doulias PT, Ischiropoulos H, Townsend RR, Margulies KB, Cappola TP, Poole DC, Chirinos JA. Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation. 2015 Jan 27;131(4):371-80; discussion 380. doi: 10.1161/CIRCULATIONAHA.114.012957. Epub 2014 Dec 22.
- Manetos C, Dimopoulos S, Tzanis G, Vakrou S, Tasoulis A, Kapelios C, Agapitou V, Ntalianis A, Terrovitis J, Nanas S. Skeletal muscle microcirculatory abnormalities are associated with exercise intolerance, ventilatory inefficiency, and impaired autonomic control in heart failure. J Heart Lung Transplant. 2011 Dec;30(12):1403-8. doi: 10.1016/j.healun.2011.08.020. Epub 2011 Oct 7.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2013
Primary Completion (Actual)
September 1, 2014
Study Completion (Actual)
November 1, 2014
Study Registration Dates
First Submitted
July 22, 2013
First Submitted That Met QC Criteria
August 6, 2013
First Posted (Estimate)
August 8, 2013
Study Record Updates
Last Update Posted (Estimate)
April 28, 2015
Last Update Submitted That Met QC Criteria
April 27, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01415
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure With Normal Ejection Fraction
-
Massachusetts General HospitalRoche DiagnosticsRecruitingCardiovascular Risk Factor | Heart Failure With Reduced Ejection Fraction | Heart Failure With Normal Ejection Fraction | Heart Failure, Right Sided | Heart Failure With Mid Range Ejection FractionUnited States
-
Medical University of South CarolinaCompletedHeart Failure | Heart Failure With Reduced Ejection Fraction | Heart Failure With Normal Ejection FractionUnited States
-
Massachusetts General HospitalNational Heart, Lung, and Blood Institute (NHLBI); Beth Israel Deaconess Medical... and other collaboratorsActive, not recruitingHeart Failure With Reduced Ejection Fraction | Heart Failure With Normal Ejection Fraction | Acute Congestive Heart FailureUnited States
-
Memorial Hospital of Rhode IslandUniversity of California, San Diego; National Heart, Lung, and Blood Institute... and other collaboratorsUnknownHeart Failure | Physical Activity | Elderly | Heart Failure With Reduced Ejection Fraction | Heart Failure With Normal Ejection Fraction | Women | Strength TrainingUnited States
-
CorAssist Cadiovascular Ltd.TerminatedHeart Failure With Normal Ejection Fraction
-
University of BaselClinical Trial Unit, University Hospital Basel, SwitzerlandRecruitingHigh-intensity Interval Training in Heart Failure Patients With Preserved Ejection Fraction (HIT-HF)Heart Failure With Normal Ejection FractionSwitzerland
-
Goethe UniversityDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)CompletedHeart Failure With Normal Ejection FractionGermany
-
University Hospitals Coventry and Warwickshire...CompletedHeart Failure With Normal Ejection FractionUnited Kingdom
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
University of Texas Southwestern Medical CenterActive, not recruitingHeart Failure With Normal Ejection FractionUnited States
Clinical Trials on Nitrate rich beetroot juice
-
University of Colorado, BoulderRecruitingChronic Kidney DiseaseUnited States
-
University of FloridaRecruitingCoronary Artery DiseaseUnited States
-
University of ExeterCompletedCognitive Change | Blood Pressure | Functional Capacity | Brain MetabolismUnited Kingdom
-
Bangor UniversityCompleted
-
University of Sao PauloRecruitingCardiovascular Abnormalities | Steroid AbuseBrazil
-
University of ReadingSaudi Cultural BureauCompletedNo Dental Disease | Non-smokingUnited Kingdom
-
Universidad Autonoma de MadridUniversidad Politecnica de Madrid; Camilo Jose Cela UniversityCompletedNitrates | Nutrition | Physical Performance | Sport Physiology | Elite Athletes
-
Queen's UniversityCompletedHeart Failure, Systolic
-
Maastricht University Medical CenterCompletedHigh Intensity Intermittent Sports PerformanceNetherlands
-
University of Sao PauloRecruitingMotor Activity | Physical Inactivity | Postmenopausal; MenorrhagiaBrazil